News

Pharnext’s PXT3003 Granted Priority Review in China for Charcot-Marie-Tooth Type 1A

The French biopharmaceutical company Pharnext recently announced that its candidate for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A) was granted priority review by the China Food and Drug Administration (CFDA). PXT3003 is a fixed-dose combination of baclofen, naltrexone, and sorbitol. The therapy candidate has received orphan drug status in both…

Micro RNA Variant Found that May Be Linked to CMT1A Outcomes

A specific mutation in a small RNA molecule called miR-149 was found to be linked to both age of onset and severity in patients with Charcot-Marie-Tooth disease type 1A (CMT1A), according to researchers. Their study, “Association of miR-149 polymorphism with onset age and severity in Charcot-Marie-Tooth disease…